Ditchcarbon
  • Contact
  1. Organizations
  2. Crucell N.V.
Public Profile
Pharmaceutical Preparation Manufacturing
NL
updated 2 months ago

Crucell N.V. Sustainability Profile

Company website

Crucell N.V., a prominent biopharmaceutical company headquartered in the Netherlands, has established itself as a leader in the development of innovative vaccines and therapeutic proteins. Founded in 1993, Crucell has made significant strides in the industry, particularly in the fields of infectious diseases and monoclonal antibodies. With a strong operational presence across Europe and North America, Crucell focuses on creating unique products that leverage its proprietary technologies, such as the PER.C6® cell line. This advanced platform enables the efficient production of high-quality biopharmaceuticals, setting Crucell apart in a competitive market. Recognised for its commitment to research and development, Crucell has achieved notable milestones, including successful collaborations and partnerships that enhance its market position. The company continues to drive advancements in vaccine development, contributing to global health initiatives and improving patient outcomes.

DitchCarbon Score

How does Crucell N.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

74

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Crucell N.V.'s score of 74 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.

86%

Let us know if this data was useful to you

Crucell N.V.'s reported carbon emissions

Inherited from Johnson & Johnson

Crucell N.V., headquartered in the Netherlands (NL), currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Johnson & Johnson, which influences its climate commitments and initiatives. Crucell N.V. inherits its climate targets and initiatives from Johnson & Johnson, which has established Science-Based Targets Initiative (SBTi) commitments aimed at reducing greenhouse gas emissions across its operations. These targets are cascaded down to Crucell N.V. as part of its corporate family relationship. While specific reduction targets for Crucell N.V. are not detailed, the overarching goals set by Johnson & Johnson include significant reductions in Scope 1, 2, and 3 emissions, aligning with industry standards for climate action. The company is also involved in initiatives such as the Carbon Disclosure Project (CDP) and RE100, which further demonstrate its commitment to sustainability and transparency in emissions reporting. In summary, while Crucell N.V. does not provide specific emissions data, it is actively engaged in climate commitments through its association with Johnson & Johnson, focusing on substantial reductions in carbon emissions as part of a broader corporate sustainability strategy.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

19902006200720082009201020112012201320142015201620172018201920202021202220232024
Scope 1
308,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
-
-
-
-
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
751,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
-
-
-
-
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 3
-
-
-
-
-
-
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
-
-
-
-
00,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

How Carbon Intensive is Crucell N.V.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Crucell N.V.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Crucell N.V.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Crucell N.V. is in NL, which has a very low grid carbon intensity relative to other regions.

Crucell N.V.'s Scope 3 Categories Breakdown

Crucell N.V.'s Scope 3 emissions, which decreased by 2% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 72% of Scope 3 emissions.

Top Scope 3 Categories

2024
Purchased Goods and Services
72%
Upstream Transportation & Distribution
9%
Business Travel
7%
Capital Goods
3%
Employee Commuting
3%
Fuel and Energy Related Activities
2%
Use of Sold Products
2%
End-of-Life Treatment of Sold Products
<1%
Upstream Leased Assets
<1%

Crucell N.V.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Crucell N.V. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Crucell N.V.'s Emissions with Industry Peers

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated about 12 hours ago

Moderna

US
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Roche Holding AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Wacker Chemie

DE
•
Chemicals nec
Updated about 18 hours ago

Illumina

US
•
Research and development services (73)
Updated 11 days ago

LANXESS Corporation

US
•
Plastics, basic
Updated about 2 months ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251031.5
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy